{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T20:31:28Z","timestamp":1764793888577},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["onlinecjc.ca","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.cjca.2015.09.012","type":"journal-article","created":{"date-parts":[[2015,9,26]],"date-time":"2015-09-26T14:01:10Z","timestamp":1443276070000},"page":"814-823","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Uninterrupted New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Ablation of Atrial Fibrillation: A Meta-analysis"],"prefix":"10.1016","volume":"32","author":[{"given":"Ramez","family":"Nairooz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karam","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Partha","family":"Sardar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Payne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Almomani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naga Venkata","family":"Pothineni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fnu","family":"Shailesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debabrata","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2015.09.012_bib1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.hrthm.2011.12.016","volume":"9","author":"Calkins","year":"2012","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2015.09.012_bib2","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/europace\/euv190","volume":"17","author":"Sticherling","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.cjca.2015.09.012_bib3","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1161\/CIRCULATIONAHA.113.006426","volume":"129","author":"Di Biase","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2015.09.012_bib4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/CIRCEP.111.964916","article-title":"Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis","volume":"5","author":"Santangeli","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.cjca.2015.09.012_bib5","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2013.11.039","article-title":"Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry","volume":"63","author":"Lakkireddy","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2015.09.012_bib6","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.hrthm.2015.02.028","article-title":"Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study","volume":"12","author":"Di Biase","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2015.09.012_bib7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/jce.12143","article-title":"Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation","volume":"24","author":"Maddox","year":"2013","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.cjca.2015.09.012_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/CIRCEP.109.859116","article-title":"Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation","volume":"3","author":"Cappato","year":"2010","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.cjca.2015.09.012_bib9","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2015.09.012_bib10","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2015.09.012_bib11","unstructured":"8. Assessing risk of bias in included studies. In: Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011). Available at: http:\/\/www.cochrane-handbook.org. Accessed November 28, 2015."},{"key":"10.1016\/j.cjca.2015.09.012_bib12","unstructured":"Wells G, Shea B, O\u2019Connell D, et\u00a0al. Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed November 28, 2015."},{"key":"10.1016\/j.cjca.2015.09.012_bib13","series-title":"The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.2","author":"The Nordic Cochrane Centre","year":"2012"},{"key":"10.1016\/j.cjca.2015.09.012_bib14","unstructured":"16.9.5. Validity of methods of meta-analysis for rare events. In: Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011). Available at: http:\/\/www.cochrane-handbook.org. Accessed November 28, 2015."},{"key":"10.1016\/j.cjca.2015.09.012_bib15","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","article-title":"Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation","volume":"36","author":"Cappato","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2015.09.012_bib16","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.hrthm.2015.04.016","article-title":"Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation","volume":"12","author":"Nagao","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2015.09.012_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.amjcard.2014.10.005","article-title":"Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon","volume":"115","author":"Kaess","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2015.09.012_bib18","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/CIRCEP.114.001586","article-title":"Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures","volume":"7","author":"Dillier","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.cjca.2015.09.012_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10840-012-9719-9","article-title":"Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin","volume":"35","author":"Konduru","year":"2012","journal-title":"J\u00a0Interv Cardiol Electrophysiol"},{"key":"10.1016\/j.cjca.2015.09.012_bib20","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijcard.2015.03.376","article-title":"Meta-analysis of major bleeding with uninterrupted warfarin compared to interrupted warfarin and heparin bridging in ablation of atrial fibrillation","volume":"187","author":"Nairooz","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2015.09.012_bib21","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/europace\/euu196","article-title":"Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban","volume":"16","author":"Winkle","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.cjca.2015.09.012_bib22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.amjcard.2014.10.002","article-title":"RE-CIRCUIT study-randomized evaluation of dabigatran etexilate compared to warfarin in pulmonary vein ablation: assessment of an uninterrupted periprocedural anticoagulation strategy","volume":"115","author":"Calkins","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2015.09.012_bib23","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.amjcard.2013.12.027","article-title":"Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation","volume":"113","author":"Sardar","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2015.09.012_bib24","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/heartjnl-2013-304386","article-title":"Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis","volume":"100","author":"Provid\u00eancia","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2015.09.012_bib25","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.amjcard.2014.05.038","article-title":"Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation","volume":"114","author":"Aryal","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2015.09.012_bib26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijcard.2015.03.323","article-title":"Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation","volume":"187","author":"Nairooz","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2015.09.012_bib27","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.cjca.2013.07.005","article-title":"Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis","volume":"29","author":"Shurrab","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2015.09.012_bib28","doi-asserted-by":"crossref","first-page":"e0126512","DOI":"10.1371\/journal.pone.0126512","article-title":"Efficacy and safety of non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis","volume":"10","author":"Santarpia","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2015.09.012_bib29","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939\u2013an oral, direct Factor Xa inhibitor\u2013after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2015.09.012_bib30","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/heartjnl-2015-307489","article-title":"Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis","volume":"101","author":"Caldeira","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2015.09.012_bib31","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.09.012_bib32","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.09.012_bib33","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.09.012_bib34","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/1060028014563950","article-title":"Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation","volume":"49","author":"Armbruster","year":"2015","journal-title":"Ann Pharmacother"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X15014373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X15014373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T01:24:35Z","timestamp":1537320275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X15014373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0828282X15014373"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2015.09.012","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uninterrupted New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Ablation of Atrial Fibrillation: A Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2015.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}